Given the molecular parallels between HAC and AFP-secreting HCC, therapeutic strategies such as AFP-targeted CAR T cells, immune checkpoint inhibitors (for PD-L1+ cases), and TKIs (e.g., sorafenib) warrant clinical investigation. The gene discussed is CD274; the disease is hepatocellular carcinoma.